Peter Blume-Jensen of Metamark Genetics on Prognosis Determinants – Video




Peter Blume-Jensen of Metamark Genetics on Prognosis Determinants
Peter Blume-Jensen, Chief Scientific Officer of Metamark Genetics, sits down with Slone Partners at the Personalized Medicine Conference in Boston to discuss their novel platform Prognosis Determinant. "Through its proprietary Prognosis Determinant trade; Discovery Platform, Metamark has identified and validated functionally active genetic determinants of metastasis that are critical to the progression of a broad spectrum of tumor types." - http://www.metamarkgenetics.com The 8th Annual Personalized Medicine Conference was hosted at Harvard Medical School by Partners Healthcare.From:SlonePartnersMediaViews:10 0ratingsTime:02:41More inScience Technology

See original here:

Peter Blume-Jensen of Metamark Genetics on Prognosis Determinants - Video

Related Posts

Comments are closed.